CiRC is a privately held, cell therapy company, developing treatments for serious diseases with high, unmet needs with an initial focus on the eye. Founded in 2019, CiRC is in pre-clinical development for the use of chemically induced retinal cells for vision restoration and specifically pursuing a treatment for Geographic Atrophy Age-Related Macular Degeneration (“Dry AMD”) and advanced Retinitis Pigmentosa (RP). Stem cells have generated considerable excitement, but CiRC’s technology bypasses the need for stem cells by transforming ordinary skin cells into specialized retinal cells using a cocktail of small molecules.
Sai Chavala, M.D., Receives ARVO Foundation Ludwig Von Sallmann Clinician-Scientist Award
CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP)